159 related articles for article (PubMed ID: 36758683)
1. DNMT3A R882H mutation promotes acute leukemic cell survival by regulating glycolysis through the NRF2/NQO1 axis.
Chu X; Zhong L; Dan W; Wang X; Zhang Z; Liu Z; Lu Y; Shao X; Zhou Z; Chen S; Liu B
Cell Signal; 2023 May; 105():110626. PubMed ID: 36758683
[TBL] [Abstract][Full Text] [Related]
2. DNMT3A R882H mutation drives daunorubicin resistance in acute myeloid leukemia via regulating NRF2/NQO1 pathway.
Chu X; Zhong L; Dan W; Wang X; Zhang Z; Liu Z; Lu Y; Shao X; Zhou Z; Chen S; Liu B
Cell Commun Signal; 2022 Oct; 20(1):168. PubMed ID: 36303144
[TBL] [Abstract][Full Text] [Related]
3. DNMT3A mutation promotes leukemia development through NAM-NAD metabolic reprogramming.
Yang X; Wang X; Yang Y; Li Z; Chen Y; Shang S; Wang Y
J Transl Med; 2023 Jul; 21(1):481. PubMed ID: 37464424
[TBL] [Abstract][Full Text] [Related]
4. Novel impact of the DNMT3A R882H mutation on GSH metabolism in a K562 cell model established by TALENs.
Yang L; Liu Y; Zhang N; Ding X; Zhang W; Shen K; Huang L; Zhou J; Cui S; Zhu Z; Hu Z; Xiao M
Oncotarget; 2017 May; 8(18):30395-30409. PubMed ID: 28418922
[TBL] [Abstract][Full Text] [Related]
5. Genetic and Epigenetic Perturbations by DNMT3A-R882 Mutants Impaired Apoptosis through Augmentation of PRDX2 in Myeloid Leukemia Cells.
Bera R; Chiu MC; Huang YJ; Liang DC; Lee YS; Shih LY
Neoplasia; 2018 Nov; 20(11):1106-1120. PubMed ID: 30245403
[TBL] [Abstract][Full Text] [Related]
6. The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers.
Russler-Germain DA; Spencer DH; Young MA; Lamprecht TL; Miller CA; Fulton R; Meyer MR; Erdmann-Gilmore P; Townsend RR; Wilson RK; Ley TJ
Cancer Cell; 2014 Apr; 25(4):442-54. PubMed ID: 24656771
[TBL] [Abstract][Full Text] [Related]
7. Effect of
Tabatabaei T; Rezvany MR; Ghasemi B; Vafaei F; Zadeh MK; Zaker F; Salmaninejad A
Biomed Res Int; 2024; 2024():9625043. PubMed ID: 38807916
[TBL] [Abstract][Full Text] [Related]
8. DNMT3A(R882H) mutant and Tet2 inactivation cooperate in the deregulation of DNA methylation control to induce lymphoid malignancies in mice.
Scourzic L; Couronné L; Pedersen MT; Della Valle V; Diop M; Mylonas E; Calvo J; Mouly E; Lopez CK; Martin N; Fontenay M; Bender A; Guibert S; Dubreuil P; Dessen P; Droin N; Pflumio F; Weber M; Gaulard P; Helin K; Mercher T; Bernard OA
Leukemia; 2016 Jun; 30(6):1388-98. PubMed ID: 26876596
[TBL] [Abstract][Full Text] [Related]
9. XPO1 inhibition displays anti-leukemia efficacy against DNMT3A-mutant acute myeloid leukemia via downregulating glutathione pathway.
Cai X; Liu Y; Li H; Que Y; Xiao M; Wang Y; Wang X; Li D
Ann Hematol; 2024 Mar; ():. PubMed ID: 38519605
[TBL] [Abstract][Full Text] [Related]
10. Preferential Self-interaction of DNA Methyltransferase DNMT3A Subunits Containing the R882H Cancer Mutation Leads to Dominant Changes of Flanking Sequence Preferences.
Mack A; Emperle M; Schnee P; Adam S; Pleiss J; Bashtrykov P; Jeltsch A
J Mol Biol; 2022 Apr; 434(7):167482. PubMed ID: 35131259
[TBL] [Abstract][Full Text] [Related]
11. Structural basis for impairment of DNA methylation by the DNMT3A R882H mutation.
Anteneh H; Fang J; Song J
Nat Commun; 2020 May; 11(1):2294. PubMed ID: 32385248
[TBL] [Abstract][Full Text] [Related]
12. Study on the Immune Escape Mechanism of Acute Myeloid Leukemia With DNMT3A Mutation.
Que Y; Li H; Lin L; Zhu X; Xiao M; Wang Y; Zhu L; Li D
Front Immunol; 2021; 12():653030. PubMed ID: 34093541
[TBL] [Abstract][Full Text] [Related]
13. Quantitative detection of DNMT3A R882H mutation in acute myeloid leukemia.
Berenstein R; Blau IW; Suckert N; Baldus C; Pezzutto A; Dörken B; Blau O
J Exp Clin Cancer Res; 2015 May; 34(1):55. PubMed ID: 25994761
[TBL] [Abstract][Full Text] [Related]
14. DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia.
Rau RE; Rodriguez BA; Luo M; Jeong M; Rosen A; Rogers JH; Campbell CT; Daigle SR; Deng L; Song Y; Sweet S; Chevassut T; Andreeff M; Kornblau SM; Li W; Goodell MA
Blood; 2016 Aug; 128(7):971-81. PubMed ID: 27335278
[TBL] [Abstract][Full Text] [Related]
15. DNMT3A Mutation-Induced CDK1 Overexpression Promotes Leukemogenesis by Modulating the Interaction between EZH2 and DNMT3A.
Yang Y; Dai Y; Yang X; Wu S; Wang Y
Biomolecules; 2021 May; 11(6):. PubMed ID: 34067359
[No Abstract] [Full Text] [Related]
16. The R882H DNMT3A hot spot mutation stabilizes the formation of large DNMT3A oligomers with low DNA methyltransferase activity.
Nguyen TV; Yao S; Wang Y; Rolfe A; Selvaraj A; Darman R; Ke J; Warmuth M; Smith PG; Larsen NA; Yu L; Zhu P; Fekkes P; Vaillancourt FH; Bolduc DM
J Biol Chem; 2019 Nov; 294(45):16966-16977. PubMed ID: 31582562
[TBL] [Abstract][Full Text] [Related]
17. The DNMT3A R882H mutant displays altered flanking sequence preferences.
Emperle M; Rajavelu A; Kunert S; Arimondo PB; Reinhardt R; Jurkowska RZ; Jeltsch A
Nucleic Acids Res; 2018 Apr; 46(6):3130-3139. PubMed ID: 29518238
[TBL] [Abstract][Full Text] [Related]
18. Structure-guided functional suppression of AML-associated DNMT3A hotspot mutations.
Lu J; Guo Y; Yin J; Chen J; Wang Y; Wang GG; Song J
Nat Commun; 2024 Apr; 15(1):3111. PubMed ID: 38600075
[TBL] [Abstract][Full Text] [Related]
19. CD44v6 chimeric antigen receptor T cell specificity towards AML with FLT3 or DNMT3A mutations.
Tang L; Huang H; Tang Y; Li Q; Wang J; Li D; Zhong Z; Zou P; You Y; Cao Y; Kong Y; Guo A; Zhou S; Li H; Meng F; Xiao Y; Zhu X
Clin Transl Med; 2022 Sep; 12(9):e1043. PubMed ID: 36163632
[TBL] [Abstract][Full Text] [Related]
20. CpG Island Hypermethylation Mediated by DNMT3A Is a Consequence of AML Progression.
Spencer DH; Russler-Germain DA; Ketkar S; Helton NM; Lamprecht TL; Fulton RS; Fronick CC; O'Laughlin M; Heath SE; Shinawi M; Westervelt P; Payton JE; Wartman LD; Welch JS; Wilson RK; Walter MJ; Link DC; DiPersio JF; Ley TJ
Cell; 2017 Feb; 168(5):801-816.e13. PubMed ID: 28215704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
